{"id":147253,"date":"2025-01-28T14:02:03","date_gmt":"2025-01-28T13:02:03","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=147253"},"modified":"2025-01-28T14:39:21","modified_gmt":"2025-01-28T13:39:21","slug":"zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/","title":{"rendered":"Zenas BioPharma to present at the Guggenheim SMID Cap Biotech Conference"},"content":{"rendered":"

Statement issued by the company (Announcement)<\/p>\n

\n

Zenas BioPharma<\/strong>, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies<\/strong>, today announced management\u2019s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference<\/strong> on Wednesday, February 5, 2025, at 3:00 p.m. ET.<\/p>\n

A live webcast and archived replay of the Company\u2019s presentation can be accessed under \u201cEvents and Presentations\u201d in the Investor & Media Relations<\/a> section of the Zenas BioPharma website<\/a>.<\/p>\n

About Zenas BioPharma, Inc.<\/h2>\n

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas\u2019 lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19<\/strong> and Fc\u03b3RIIb<\/strong>, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab\u2019s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit\u00a0www.zenasbio.com<\/a>\u00a0and follow us on LinkedIn<\/a>.<\/p>\n

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.<\/p>\n

Investor Contact:<\/strong>\r\n\r\nMatthew Osborne\r\n\r\nInvestor Relations and Corporate Communications\r\nMatt.osborne@zenasbio.com<\/a>\r\n\r\nMedia Contact<\/strong>:\r\nArgot Partners\r\n\r\nZenas@argotpartners.com<\/a><\/pre>\n
AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Statement issued by the company (Announcement) Zenas BioPharma, Inc. (\u201cZenas\u201d or the \u201cCompany\u201d) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization […]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[125518],"tags":[],"class_list":["post-147253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"\nZenas BioPharma - Guggenheim SMID Cap Biotech Conference<\/title>\n<meta name=\"description\" content=\"Zenas BioPharma announced management\u2019s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zenas BioPharma - Guggenheim SMID Cap Biotech Conference","description":"Zenas BioPharma announced management\u2019s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Zenas BioPharma to present at the Guggenheim SMID Cap Biotech Conference","datePublished":"2025-01-28T13:02:03+00:00","dateModified":"2025-01-28T13:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/"},"wordCount":338,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/","url":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/","name":"Zenas BioPharma - Guggenheim SMID Cap Biotech Conference","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2025-01-28T13:02:03+00:00","dateModified":"2025-01-28T13:39:21+00:00","description":"Zenas BioPharma announced management\u2019s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Zenas BioPharma to present at the Guggenheim SMID Cap Biotech Conference"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-Cj3","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/147253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=147253"}],"version-history":[{"count":3,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/147253\/revisions"}],"predecessor-version":[{"id":147279,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/147253\/revisions\/147279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=147253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=147253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=147253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}